Benjamin W Johnson, 475049 Marc Dr, Nashville, TN 37211

7803837, Sep 28, 2010

Nov 21, 2006

11/602551

Jae-Kyu Jung - San Diego CA, US
Graeme Semple - San Diego CA, US
Benjamin R. Johnson - San Diego CA, US

Arena Pharmaceuticals, Inc. - San Diego CA

A61K 31/341
A61K 31/381
C07D 307/32
C07D 409/04

514444, 514473, 549 60, 549479

System for selecting a color shade comprising a very small number of color display cards with mixed shades of two or more colors. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed shade for making paint in the desired color tone.

8507473, Aug 13, 2013

Sep 10, 2009

13/063305

P. Douglas Boatman - San Diego CA, US
Benjamin R. Johnson - San Diego CA, US
Jae-Kyu Jung - San Diego CA, US
Michelle Kasem - Chula Vista CA, US
Thomas O. Schrader - San Diego CA, US
Philip J. Skinner - San Diego CA, US
Steven Colletti - Princeton Junction NJ, US

Arena Pharmaceuticals, Inc. - San Diego CA
Merck Sharp & Dohme Corp. - Rahway NJ

C07D 471/04
A61K 31/437
A61K 31/55
A61P 3/06
A61P 3/10
A61P 9/10

51421707, 514303, 546118, 540597

The present invention is directed to certain 3H-imidazo[4,5-b]pyridin-5-ol derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the GPR81 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of GPR81 associated disorders, for example, dyslipidemia, atherosclerosis, atheromatous disease, hypertension, coronary heart disease, stroke, insulin resistance, impaired glucose tolerance, type 2 diabetes, syndrome X, obesity, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type 1 diabetes and acne.

2007009, Apr 26, 2007

Nov 18, 2004

10/578732

Jae-Kyu Jung - San Diego CA, US
Graeme Semple - San Diego CA, US
Benjamin Johnson - San Diego CA, US

ARENA PHARMACEUTICALS, INC. - San Diego CA

A61K 31/381
A61K 31/34
C07D 409/02

514444000, 514473000, 549060000, 549470000

System for selecting a colour shade comprising a very small number of colour display cards with mixed shades of two or more colours. The system comprises means for selecting one shade among mixed shades, means for presenting the selected mixed shade as well as means for specifying the selected mixed shade for making paint in the desired colour tone.

2012032, Dec 27, 2012

Mar 2, 2011

13/581846

Robert M. Jones - San Diego CA, US
Daniel J. Buzard - San Diego CA, US
Tawfik Gharbaoui - Escondido CA, US
Benjamin R. Johnson - San Diego CA, US
Michelle Kasem - Chula Vista CA, US
Thomas O. Schrader - San Diego CA, US
Scott Stirn - San Diego CA, US

ARENA PHARMACEUTICALS, INC. - San Diego CA

C07D 487/04
C07C 41/01
A61P 37/00
A61P 9/10
A61P 3/10
A61P 17/10
A61P 1/16
A61P 17/06
A61K 31/407
A61P 1/04

514411, 548428, 568655

The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions eases characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).

2015028, Oct 8, 2015

Jun 15, 2015

14/739341

- San Diego CA, US
Daniel J. Buzard - San Diego CA, US
Tawfik Gharbaoui - Escondido CA, US
Benjamin R. Johnson - San Diego CA, US
Michelle Kasem - Chula Vista CA, US
Thomas O. Schrader - San Diego CA, US
Scott Stirn - San Diego CA, US

ARENA PHARMACEUTICALS, INC. - San Diego CA

C07D 487/04

The present invention relates to salts, processes, and process intermediates useful in the preparation of (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid of Formula (Ia), salts, and crystalline forms thereof. The compound (R)-2-(9-chloro-7-(4-isopropoxy-3-(trifluoromethyl)benzyloxy)-2,3-dihydro-1H-pyrrolo[1,2-a]indol-1-yl)acetic acid has been identified as an S1P1 receptor modulator that is useful in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis).